This collaboration aims at accelerating the discovery of small molecules across various therapeutic areas, leveraging its unique Deep Physics platform combined with Generative AI. AQEMIA to receive up to a total of $140M in upfront and milestones across all...

A single dose of measles and rubella (MR) vaccine delivered to adults by the Vaxxas high-density microarray patch (HD-MAP) provided antibody responses comparable to the same vaccine delivered by needle and syringe. Higher antibody responses in study participants with the...

Positive results from the TELLOMAK Phase 2 Trial with lacutamab in heavily pretreated patients with relapsed and refractory Sézary syndrome selected for oral presentation Preliminary monotherapy lacutamab Phase 1b clinical data and pre-clinical combinability data in patients with peripheral T-cell...

ExxonMobil aims to churn out even more discoveries in Guyana’s Stabroek block with three wildcats planned for the new year, said its senior vice president, Neil Chapman, on October 27.  Exxon has already racked up a resource count of over...

Avutometinib + Sotorasib Combination Demonstrated Preliminary Efficacy with Confirmed Responses in both KRAS G12C Inhibitor Resistant and Naïve Patients No New Safety Signals Observed in Combination; Most Treatment-Related Adverse Events Mild to Moderate Enrollment of Patients Naïve to or Previously Treated...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the poster presentation of a Phase I/II trial of alisertib plus pembrolizumab for the treatment of patients with Rb-deficient head and neck squamous cell carcinoma (Clinicaltrials.gov identifier NCT04555837)...

LOS ANGELES--(BUSINESS WIRE)--Faraday Future Intelligent Electric Inc. (NASDAQ: FFIE) (“Faraday Future”, “FF” or “Company”), a California-based global shared intelligent electric mobility ecosystem company, today delivered the Ultimate AI TechLuxury FF 91 2.0 Futurist Alliance to its Founder and Chief...

ExxonMobil, Hess and CNOOC, have reached a significant cost recovery milestone as they develop the immensely lucrative Stabroek Block. As of the first half of 2023, the Stabroek Block partners have successfully recovered over US$14 billion in investments. This...

– ALINA data demonstrate Alecensa reduces disease recurrence in the early setting for people with ALK-positive non-small cell lung cancer (NSCLC), building on its long-established benefit in the advanced setting – – About half of people with NSCLC experience disease...

ROOT, Switzerland--(BUSINESS WIRE)--$NVCR--Novocure (NASDAQ: NVCR) announced today that data from the randomized phase 3 LUNAR clinical trial evaluating the use of Tumor Treating Fields (TTFields) therapy together with standard systemic therapies for the treatment of metastatic non-small cell lung...